← Back to headlines
Matinas BioPharma Receives NYSE Notice Over Equity Shortfall
Matinas BioPharma has received a notice from the NYSE regarding an equity shortfall, granting the company until 2027 to comply with the exchange's listing requirements.
26 Jun, 21:38 — 26 Jun, 21:38
Sources
Showing 1 of 1 sources
Related Stories
HDFC Bank CEO Sashidhar Jagdishan to Step Down in October
39m ago
FSSAI Bans Everest and Laljee Godhoo From Selling Substandard Hing Powder
1h ago
UAE Central Bank Launches Probe Into Banque Misr Over US Money Laundering Warnings
2h ago
S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight - Reuters
2h ago